$33.7M
+$33.7M this year1 filing since 2026 · latest Equity filed
NextPoint Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing precision immuno-oncology and tumor-directed therapeutics against the B7-H7 (HHLA2) checkpoint axis. Its programs pair direct tumor killing with immunomodulation and are guided by a clinical biomarker used to select B7-H7-positive patients. The pipeline includes a tri-functional checkpoint inhibitor in Phase 1, a T cell engager, and an antibody-drug conjugate. The company was founded out of MPM Capital and has raised Series B financing co-led by Leaps by Bayer and Sanofi Ventures.
What sets it apart
It is built around B7-H7/HHLA2, a checkpoint axis distinct from PD-1/PD-L1, and pairs each therapeutic with a validated clinical biomarker to target patients who do not benefit from PD-1/L1 inhibitors.
A tri-functional B7-H7-directed checkpoint inhibitor in Phase 1 clinical trials that blocks the B7-H7/KIR3DL3 interaction, enhances TMIGD2 co-stimulation, and drives antibody-dependent cellular cytotoxicity.
